Shire PLC said it increased the maximum tender amount of certain outstanding senior notes of its unit Baxalta to $2.33 billion from $2.25 billion.
Illinois-based Baxalta, Shire's wholly owned subsidiary, develops products for hemophilia, immunology and oncology.
Other terms and conditions for the tender offer remain unchanged, the Dublin-based biotechnology company said.
Citigroup Global Markets Ltd. and Morgan Stanley & Co. LLC are acting as dealer managers, with Global Bondholder Services Corp. acting as depository and information agent.